Clinical trial
MK0991 in Combination With Standard Antifungal Agent(s) for the Treatment of…
NCT00076869 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00076869 |
|---|---|
| Title | MK0991 in Combination With Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis (0991-037) |
| Official title | A Multicenter, Open, Noncomparative Study to Estimate the Safety, Tolerability, and Efficacy of MK0991 in Combination With Amphotericin B, Lipid Formulations of Amphotericin B, or Azoles in the Treatment of Invasive Aspergillus Infection in Adults Who Are Refractory to or Intolerant of Standard… |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Aspergillosis |
| Intervention type | Drug |
| Interventions | MK0991, caspofungin acetate, Comparator: amphotericin B, Comparator: lipid formulation of amphotericin B and/or azole |
| Enrollment | 55 |
| Start date | Jan 1, 2003 |
| Primary completion | Sep 1, 2004 |
| Completion | Aug 1, 2005 |
| First posted | Feb 6, 2004 |
| Last update posted | Jan 13, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: